BRCA1 and neoplasm: In our present study evaluating the benefit of adjuvant capecitabine, the HR of 0.66 for RFS in BRCA1-like TNBC patients is indicative of a clinical benefit of the addition of capecitabine in tumours with HRD, although no statistical significance was achieved.